Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study
نویسندگان
چکیده
Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium. Paliperidone palmitate once monthly, risperidone microspheres, haloperidol decanoate, and olanzapine pamoate were studied. This study demonstrated significantly higher treatment continuation of paliperidone palmitate once monthly compared to risperidone microspheres (p-value<0,01) and haloperidol decanoate (p-value<0,01) in both countries, a significantly higher treatment continuation of paliperidone palmitate once monthly compared to olanzapine pamoate in the Netherlands (p-value<0,01), and a general trend towards better treatment continuation versus olanzapine pamoate in Belgium. Analysing the subgroup of patients without previous exposure to long-acting antipsychotic treatment revealed the positive impact of previous exposure on treatment continuation with a subsequent long acting treatment. Additionally, the probability of restarting the index therapy was higher among patients treated with paliperidone palmitate once monthly compared to patients treated with risperidone microspheres and haloperidol decanoate. The data source used and the methodology defined ensured for the first time a comparison of treatment continuation in a non-interventional study design for the four long-acting injectable antipsychotics studied.
منابع مشابه
Treatment Continuation And Treatment Characteristics Of Four Long Acting Antipsychotic Medications (Paliperidone Palmitate, Risperidone Microspheres, Olanzapine Pamoate And Haloperidol Decanoate) In The Netherlands.
متن کامل
One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
OBJECTIVE Treatment discontinuation is a major problem in routine clinical settings and is associated with poorer outcomes for conditions like schizophrenia. Risperidone long-acting injection (RLAI) has shown low discontinuation and good tolerability in long-term clinical trials. This retrospective study investigated RLAI continuation in a naturalistic clinical setting in New Zealand. METHODS...
متن کاملHyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia
Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (...
متن کاملDetermination Changes of Blood Biomarker Levels in Two Treatment status of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in Patients with Long-Term Schizophrenia
Background and objectives: Schizophrenia is a chronic psychiatric disorder, which reduces the patient quality of life. Despite the recommendation for treating this disorder with a minimum dose of medications, antipsychotic polypharmacy has been used experimentally that cause increasing the drug interactions. Aripiprazole has low risk of metabolic has recommended as a first line a treatment fo...
متن کاملTreatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
OBJECTIVE This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR). METHODS Administrative data are analyzed from California Medicaid (Medi-Cal) beneficiaries with schizophrenia who initiated FD, HD, or LAR treatment. Patients were requir...
متن کامل